<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:05:49 -0700</creation_date>
  <update_date>2013-01-15 20:05:49 -0700</update_date>
  <accession>HMDBP08057</accession>
  <secondary_accessions>
    <accession>13768</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>TN-C</synonym>
  </synonyms>
  <gene_name>TNNC1</gene_name>
  <general_function>Involved in calcium ion binding</general_function>
  <specific_function>Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components:Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14969</accession>
      <name>Trifluoperazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15058</accession>
      <name>Levosimendan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15158</accession>
      <name>Felodipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15374</accession>
      <name>Bepridil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15457</accession>
      <name>Dihydroxyaluminium</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>calcium ion binding</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:3</chromosome_location>
    <locus>3p21.1</locus>
    <gene_sequence>&gt;486 bp
ATGGATGACATCTACAAGGCTGCGGTAGAGCAGCTGACAGAAGAGCAGAAAAATGAGTTC
AAGGCAGCCTTCGACATCTTCGTGCTGGGCGCTGAGGATGGCTGCATCAGCACCAAGGAG
CTGGGCAAGGTGATGAGGATGCTGGGCCAGAACCCCACCCCTGAGGAGCTGCAGGAGATG
ATCGATGAGGTGGACGAGGACGGCAGCGGCACGGTGGACTTTGATGAGTTCCTGGTCATG
ATGGTTCGGTGCATGAAGGACGACAGCAAAGGGAAATCTGAGGAGGAGCTGTCTGACCTC
TTCCGCATGTTTGACAAAAATGCTGATGGCTACATCGACCTGGATGAGCTGAAGATAATG
CTGCAGGCTACAGGCGAGACCATCACGGAGGACGACATCGAGGAGCTCATGAAGGACGGA
GACAAGAACAACGACGGCCGCATCGACTATGATGAGTTCCTGGAGTTCATGAAGGGTGTG
GAGTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>161</residue_number>
    <molecular_weight>18402.4</molecular_weight>
    <theoretical_pi>3.78</theoretical_pi>
    <pfams>
      <pfam>
        <name>efhand</name>
        <pfam_id>PF00036</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>None</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Troponin C, slow skeletal and cardiac muscles
MDDIYKAAVEQLTEEQKNEFKAAFDIFVLGAEDGCISTKELGKVMRMLGQNPTPEELQEM
IDEVDEDGSGTVDFDEFLVMMVRCMKDDSKGKSEEELSDLFRMFDKNADGYIDLDELKIM
LQATGETITEDDIEELMKDGDKNNDGRIDYDEFLEFMKGVE</protein_sequence>
  </protein_properties>
  <genbank_protein_id>4507615</genbank_protein_id>
  <uniprot_id>P63316</uniprot_id>
  <uniprot_name>TNNC1_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1LA0</pdb_id>
  </pdb_ids>
  <genbank_gene_id>NM_003280.2</genbank_gene_id>
  <genecard_id>TNNC1</genecard_id>
  <geneatlas_id>TNNC1</geneatlas_id>
  <hgnc_id>HGNC:11943</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Roher A, Lieska N, Spitz W: The amino acid sequence of human cardiac troponin-C.  Muscle Nerve. 1986 Jan;9(1):73-7.</reference_text>
      <pubmed_id>3951483</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gahlmann R, Wade R, Gunning P, Kedes L: Differential expression of slow and fast skeletal muscle troponin C. Slow skeletal muscle troponin C is expressed in human fibroblasts. J Mol Biol. 1988 May 20;201(2):379-91.</reference_text>
      <pubmed_id>3166492</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schreier T, Kedes L, Gahlmann R: Cloning, structural analysis, and expression of the human slow twitch skeletal muscle/cardiac troponin C gene. J Biol Chem. 1990 Dec 5;265(34):21247-53.</reference_text>
      <pubmed_id>2250022</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Spyracopoulos L, Li MX, Sia SK, Gagne SM, Chandra M, Solaro RJ, Sykes BD: Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry. 1997 Oct 7;36(40):12138-46.</reference_text>
      <pubmed_id>9315850</pubmed_id>
    </reference>
    <reference>
      <reference_text>Takeda S, Kobayashi T, Taniguchi H, Hayashi H, Maeda Y: Structural and functional domains of the troponin complex revealed by limited digestion. Eur J Biochem. 1997 Jun 15;246(3):611-7.</reference_text>
      <pubmed_id>9219516</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lindhout DA, Sykes BD: Structure and dynamics of the C-domain of human cardiac troponin C in complex with the inhibitory region of human cardiac troponin I. J Biol Chem. 2003 Jul 18;278(29):27024-34. Epub 2003 May 5.</reference_text>
      <pubmed_id>12732641</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R: First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum Mutat. 2001 Jun;17(6):524.</reference_text>
      <pubmed_id>11385718</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mogensen J, Murphy RT, Shaw T, Bahl A, Redwood C, Watkins H, Burke M, Elliott PM, McKenna WJ: Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2004 Nov 16;44(10):2033-40.</reference_text>
      <pubmed_id>15542288</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schmidtmann A, Lindow C, Villard S, Heuser A, Mugge A, Gessner R, Granier C, Jaquet K: Cardiac troponin C-L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C. FEBS J. 2005 Dec;272(23):6087-97.</reference_text>
      <pubmed_id>16302972</pubmed_id>
    </reference>
    <reference>
      <reference_text>Landstrom AP, Parvatiyar MS, Pinto JR, Marquardt ML, Bos JM, Tester DJ, Ommen SR, Potter JD, Ackerman MJ: Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol. 2008 Aug;45(2):281-8. Epub 2008 May 11.</reference_text>
      <pubmed_id>18572189</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pinto JR, Parvatiyar MS, Jones MA, Liang J, Ackerman MJ, Potter JD: A functional and structural study of troponin C mutations related to hypertrophic cardiomyopathy. J Biol Chem. 2009 Jul 10;284(28):19090-100. Epub 2009 May 12.</reference_text>
      <pubmed_id>19439414</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Calcium</name>
        <accession>HMDB00464</accession>
      </metabolite>
      <reference>
        <reference_text>Dweck D, Reynaldo DP, Pinto JR, Potter JD: A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding. J Biol Chem. 2010 Jun 4;285(23):17371-9. Epub 2010 Apr 6.</reference_text>
        <pubmed_id>20371872</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Calcium</name>
        <accession>HMDB00464</accession>
      </metabolite>
      <reference>
        <reference_text>Swindle N, Tikunova SB: Hypertrophic cardiomyopathy-linked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C. Biochemistry. 2010 Jun 15;49(23):4813-20.</reference_text>
        <pubmed_id>20459070</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Calcium</name>
        <accession>HMDB00464</accession>
      </metabolite>
      <reference>
        <reference_text>Parvatiyar MS, Pinto JR, Liang J, Potter JD: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. J Biol Chem. 2010 Sep 3;285(36):27785-97. Epub 2010 Jun 21.</reference_text>
        <pubmed_id>20566645</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Calcium</name>
        <accession>HMDB00464</accession>
      </metabolite>
      <reference>
        <reference_text>Baylor SM, Hollingworth S: Calcium indicators and calcium signalling in skeletal muscle fibres during excitation-contraction coupling. Prog Biophys Mol Biol. 2011 May;105(3):162-79. Epub 2010 Jun 25.</reference_text>
        <pubmed_id>20599552</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60.</reference_text>
        <pubmed_id>9525919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levosimendan</name>
        <accession>HMDB15058</accession>
      </metabolite>
      <reference>
        <reference_text>Kleerekoper Q, Putkey JA: Drug binding to cardiac troponin C.  J Biol Chem. 1999 Aug 20;274(34):23932-9.</reference_text>
        <pubmed_id>10446160</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levosimendan</name>
        <accession>HMDB15058</accession>
      </metabolite>
      <reference>
        <reference_text>Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, Kilpelainen I, Haikala H: Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol. 2000 Mar;32(3):479-91.</reference_text>
        <pubmed_id>10731446</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levosimendan</name>
        <accession>HMDB15058</accession>
      </metabolite>
      <reference>
        <reference_text>Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I: Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.  J Biol Chem. 2001 Mar 23;276(12):9337-43. Epub 2000 Dec 11.</reference_text>
        <pubmed_id>11113122</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levosimendan</name>
        <accession>HMDB15058</accession>
      </metabolite>
      <reference>
        <reference_text>Sorsa T, Pollesello P, Permi P, Drakenberg T, Kilpelainen I: Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol. 2003 Sep;35(9):1055-61.</reference_text>
        <pubmed_id>12967628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levosimendan</name>
        <accession>HMDB15058</accession>
      </metabolite>
      <reference>
        <reference_text>Lehmann A, Boldt J, Lang J, Isgro F, Blome M: [Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization?]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003 Sep;38(9):577-82.</reference_text>
        <pubmed_id>12975736</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levosimendan</name>
        <accession>HMDB15058</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Felodipine</name>
        <accession>HMDB15158</accession>
      </metabolite>
      <reference>
        <reference_text>Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8.</reference_text>
        <pubmed_id>3178884</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR: Interaction of bepridil with the cardiac troponin C/troponin I complex.  FEBS Lett. 2001 Sep 28;506(1):51-4.</reference_text>
        <pubmed_id>11591369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Li MX, Sykes BD: Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem. 2002 Aug 23;277(34):31124-33. Epub 2002 Jun 11.</reference_text>
        <pubmed_id>12060657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>MacLachlan LK, Reid DG, Mitchell RC, Salter CJ, Smith SJ: Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem. 1990 Jun 15;265(17):9764-70.</reference_text>
        <pubmed_id>2351672</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60.</reference_text>
        <pubmed_id>9525919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroxyaluminium</name>
        <accession>HMDB15457</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
